1. Systematic literature review on the incidence and prevalence of heart failure in children and adolescents;Shaddy;Pedia Cardiol.,2018
2. R.S. Loomba, N. Ikeda, V. Dorsey, F. Yousaf, K. Nelson-McMillan, Acute Effects of Sacubitril/Valsartan with Initial Initiation in Pediatric Patients in the Cardiac Intensive Care Unit, Pediatr Cardiol, DOI 10.1007/s00246–023-03138–5(2023).
3. Baseline characteristics of pediatric patients with heart failure due to systemic left ventricular systolic dysfunction in the PANORAMA-HF trial;Shaddy;Circ. Heart Fail,2023
4. Sacubitril/Valsartan: neprilysin inhibition 5 years after PARADIGM-HF, JACC;Docherty;Heart Fail,2020
5. Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor;Ayalasomayajula;Clin. Pharm.,2017